Compare Immunogenicity & Safety of 3 Lots of GSK208141 Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10-17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10-17 y With Healthy HSV 1 /2- Adult Females.

Trial Profile

Compare Immunogenicity & Safety of 3 Lots of GSK208141 Vaccine in Healthy HSV-1 & -2 Seronegative (HSV 1-/2-) Females of 10-17 y & Vaccine Immunogenicity in Healthy HSV 1-/2- Females of 10-17 y With Healthy HSV 1 /2- Adult Females.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Sep 2016

At a glance

  • Drugs GSK 208141 (Primary)
  • Indications Herpes simplex virus type 1 infections; Herpes simplex virus type 2 infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 06 Nov 2008 Actual patient number changed 554 to 671 from as reported by ClinicalTrials.gov.
    • 22 Aug 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top